Research programme: peptide hybrids - Amylin Pharmaceuticals
Alternative Names: AC 164209; Amylinomimetic/GRA peptide hybrid; GLP-1 receptor agonist/amylin analogue hybrid; GLP-1 receptor agonist/amylin mimetic hybrid; GLP-1 receptor agonist/amylinomimetic hybrid; GRA/amylinomimetic peptide hybrid; INTOLatest Information Update: 02 Oct 2021
At a glance
- Originator Amylin Pharmaceuticals
- Class Peptides; Recombinant fusion proteins
- Mechanism of Action Glucagon-like peptide-1 receptor agonists; Islet amyloid polypeptide stimulants
- 
          
            
              Orphan Drug Status
              NoOrphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases. 
Highest Development Phases
- Discontinued Diabetes mellitus; Obesity
